The Global Multiple Cancer Monoclonal Antibodies market size was valued at US$ 56.88 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.39 % from 2022 to 2030. Cancer monoclonal antibodies are specific antibodies with identical immune cells that are clones of a single parent cell directed to specific cellular targets. Thus, monoclonal antibodies are preciously customizable due to their unique nature and play a crucial role in treating target-specific cancerous cells. Therefore, monoclonal antibodies technology is proven to be more effective than other cancer therapies.
The increasing incidence of cancer disease among the population is driving the growth of the market. For instance, as per the World Health Organization, cancer is the second leading cause of death worldwide, accounting for around 9.6 million deaths in the year 2018. Multiple cancers, including lung cancer, colorectal cancer, prostate cancer, and liver cancer, are the most common types of cancer among men, while breast cancer, cervical cancer, colorectal cancer, and thyroid cancer are the most common among women. Additionally, increasing spending on research and development by multinational pharmaceutical companies is expected to create lucrative market growth. However, the high cost of treatment therapy and drug development may restrain the growth of the market.
The Global Multiple Cancer Monoclonal Antibodies market is segmented on the basis of product type, indication type, and region. Based on the service, the market is divided into Cetuximab, Nivolumab, Atezolizumab, Ramucirumab, Pembrolizumab, Pembrolizumab Companion Diagnostic, Ipilimumab, and Cancer Biosimilar Drugs (Bevacizumab, Trastuzumab, Nimotuzumab, etc.). On the basis of indication type, the market is divided into Lung Cancer, Bladder Cancer, Breast cancer, Endometrial cancer, Ovarian cancer, Oesophageal cancer, Prostate cancer, Multiple Myeloma, Lymphoma, Renal Cell Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and the Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
The key players of this market include Abbvie, Amgen, Bayer HealthCare, Biogen Idec, Eli Lilly, Genmab, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Roche, and Seattle Genetics, among others.